欧洲肿瘤内科学会（EMSO 2022）摘要

把过去一周开ESMO会的重要数据总结一下：
Friday 9: MONARCH 3 and TROPiCS-02
Saturday 10: Towards molecular cancer prevention, TILs versus ipilimumab 
Sunday 11:  NICHE-2, KEYNOTE-412, SWOG S1801
Monday 12: COSMIC-313, RADICALS-HD, IPSOS and CodeBreaK 200

Melissa johnson
Phase III codebreak 200 study: sotorasib vs. docetaxel, PFS HR 0.66, OS the same, better control of disease related symptoms and improved QOL. Kras G12C (13% all lung cancer, ~30% Kras)

SWOG 1801: melanoma, neoadjuvant vs. adjuvant pembro in resected stage IIIB-IV, phase II trial. 14.5m, Event free survival, HR 0.58. Neoadjuvant is better. 

IPSOS study, 1st-line Atezo in pts w/ NSCLC, not eligible for platinum. Control arm single agent chemo, 1 year OS 43.7%, 2 yr OS 24.3% in Atezo arm, improved compared to standard care. No added toxicity. Regardless histology, PS or PD-L1

FRESCO-2 study, phase III: mCRC, fruquintinib, VEGF inhibitor, 5mg days 1-21, q28, OS, HR 0.662, 7.4 vs 4.8m. 

COSMIC-313 study: RCC, 3 drugs vs. 2: Ipi/Nivo vs. Ipi/Nivo/Cabo, PFS positive, HR 0.73. OS is maturing. Intermediate and poor risk. 

Neoadjuvant ICI in dMMR (10-15% of all) colon cancer: The NICHE-2 study, 67% pCR, major RR: 95%. Lynch associated tumor has higher pCR

Keynote-412, H&N SCC stage III or IV: negative trial, chemoXRT + pembro for 17 cycles. Event free survival not meeting primary end point. 

Radicals-HD study, ADT, post radiotherapy after prostatectomy, RT alone, RT + 6m or long
Met free survival, no benefit of 6m ADT vs. no ADT. 24m is better than 6m 

Monarch 3 study: abemaciclib + AI in HR+ met breast cancer, ~493 pts, PFS positive, 2nd interim study, OS in ITT, improvement of 12m, not meeting stopping criteria, final analysis in 2023. Visceral disease patients: improvement in OS numerically, needs further f/u. 

6个月内都可以看到会议视频：
https://esmocongress.esmo.org/esmo/esmo2022/en-GB/presentation/541626